The Amyloidosis Channel is supported with funding from Prothena (Silver).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COSTEM 2021 | The role of ASCT in amyloidosis
Pieter Sonneveld, MD, PhD, Erasmus University, Rotterdam, The Netherlands, comments on the role of autologous stem cell transplantation (ASCT) in the treatment of patients with amyloidosis. Prof. Sonneveld describes how poor tolerability to intensive therapies is a major challenge to ASCT for these patients. Nevertheless, several studies have reported positive results for ASCT. In addition, Prof. Sonneveld describes how novel agents initially developed to treat myeloma have also demonstrated efficacy in amyloidosis. This interview took place at the 6th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM), which took place virtually.
